Tong Wu, Louis M Pelus, P Artur Plett, Carol H Sampson, Hui Lin Chua, Alexa Fisher, Hailin Feng, Liqiong Liu, Hongge Li, Miguel Ortiz, Supriya Chittajallu, Qianyi Luo, Ashay D Bhatwadekar, Timothy B Meyer, Xin Zhang, Daohong Zhou, Kathryn D Fischer, David L McKinzie, Steven J Miller, Christie M Orschell
Survivors of acute radiation exposure suffer from the delayed effects of acute radiation exposure (DEARE), a chronic condition affecting multiple organs, including lung, kidney, heart, gastrointestinal tract, eyes, and brain, and often causing cancer. While effective medical countermeasures (MCM) for the hematopoietic-acute radiation syndrome (H-ARS) have been identified and approved by the FDA, development of MCM for DEARE has not yet been successful. We previously documented residual bone marrow damage (RBMD) and progressive renal and cardiovascular DEARE in murine survivors of H-ARS, and significant survival efficacy of 16,16-dimethyl prostaglandin E2 (dmPGE2) given as a radioprotectant or radiomitigator for H-ARS...
May 1, 2023: Radiation Research